Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
PPLPHARMA.NSthis companyPiramal Pharma Limited	₹246.37	-55.5×	2.22×	2.04×	22.63×	-83.3%	26.9%	1.0%	-3.7%	-4.0%	0.6%	2.8%	0.7×	4.47×	0.27×	1.51×	0.1%	3	2.56	2	C
AJANTPHARM.NSAjanta Pharma Limited	₹3,344.00	33.18×	7.74×	6.43×	22.46×	64.5%	51.4%	24.3%	19.4%	23.3%	20.5%	0.4%	0.06×	0.1×	82.23×	2.64×	1.0%	5	18.51	4	A
CIPLA.NSCipla Limited	₹1,403.80	25.49×	2.87×	3.51×	15.19×	112.4%	42.7%	16.7%	13.8%	11.3%	9.8%	2.6%	0.02×	-0.06×	86.67×	3.44×	1.3%	4	9.92	4	A-
DRREDDY.NSDr. Reddy's Laboratories Limited	₹1,385.00	24.38×	2.77×	3.11×	14.13×	25.1%	52.8%	13.8%	12.8%	11.4%	7.5%	2.9%	0.24×	0.94×	12.42×	1.8×	0.6%	7	5.66	3	B+
GLAND.NSGland Pharma Limited	₹3,302.40	27.2×	2.7×	4.35×	12.94×	-57.3%	30.0%	18.8%	16.0%	9.9%	7.6%	2.6%	0.03×	-1.6×	36.24×	4.68×	1.1%	5	—	2	C+
GRANULES.NSGranules India Limited	₹799.20	25.35×	2.97×	2.81×	13.13×	-42.2%	43.0%	16.6%	11.1%	11.7%	10.1%	0.8%	0.3×	0.52×	7.77×	1.8×	0.2%	5	—	2	C+
Peer median	—	25.49×	2.87×	3.51×	14.13×	25.1%	43.0%	16.7%	13.8%	11.4%	9.8%	2.6%	0.06×	0.1×	36.24×	2.64×	1.0%	5	9.92	3	—